Abstract Body

Background: The process of HIV-1 entry is key to the replication of the virus. It is one of the most attractive targets in the search for new drugs to treat HIV-1 infection as entry inhibitors would have utility in both pre- and post-exposure prophylaxis, including woman-controlled microbicides. In the HIV-1 entry field, two main inhibitor chemotypes predominate (BMS-377806- and NBD-556-type compounds) with the BMS-377806 analogues demonstrating superior potency. However, the BMS-377806 analogues suffer from poor solubility and oral bioavailability. Therefore, given the enormous potential of small molecule entry inhibitors, we have designed and tested a series of novel compounds that function as entry inhibitors and have better predicted ADME/PK properties. Methodology: To identify novels compounds that function as entry inhibitors, we performed a high-content pharmacophore virtual screen using Blaze v10 (Cresset, UK) and a pharmacophore derived from templating BMS-377806, BMS-488043, and BMS-626529 using FieldTemplater v3.0 (Cresset, UK). 50 compounds were purchased for testing in the single round infection assay against HIV-1 pseudotyped with HIV-1 Env and AMLV Env. Spark v10 (Cresset, UK) and StarDrop v5.2 (Optibrium Ltd, UK) were employed to design a series of next generation compounds with novel scaffolds. Next generation compounds were synthesized and tested for potency and specificity in the single round infection assay. Results: Assessment of the antiviral potencies and specificity of 50 commercially available screening compounds identified 5 novel compounds previously undescribed in the literature. However, each hit contained a core piperazine; a moiety that is shared by the BMS-377806-type inhibitors. Replacement of the core piperazine with a dipyrrolidine yielded a novel inhibitor with high micromolar potency. Sequential replacements of a terminal acenaphtene ring, with varying azaindole groups resulted in an inhibitor with low nanomolar potency. However, predicted ADME/PK properties remained poor. Replacement of the dipyrrolidine with a pyrrolo-3, 4-pyrazole afforded a compound with improved predicted ADME/PK properties and that retained nanomolar potency. Conclusions: Using a combination of high-content pharmacophore virtual screening, coupled with scaffold hopping by bioisoteric replacements, and consideration of predicted ADME/PK properties, we have designed a new small molecule entry inhibitor with a novel scaffold, nanomolar potency, and improved predicted drug-like properties. This new chemotype may provide a blueprint for the future development of small molecule entry inhibitors, whilst characterization of its mechanism of action will yield important basic information about the process of HIV-1 entry.